Simplex Trading’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-11,200
| Closed | -$2K | – | 8937 |
|
|
2025
Q2 | $2K | Sell |
11,200
-100
| -0.9% | -$27 | ﹤0.01% | 8069 |
|
|
2025
Q1 | $2K | Buy |
11,300
+2,800
| +33% | +$1.45K | ﹤0.01% | 7912 |
|
|
2024
Q4 | $4K | Sell |
8,500
-8,500
| -50% | -$6.19K | ﹤0.01% | 7694 |
|
|
2024
Q3 | $16K | Sell |
17,000
-39,700
| -70% | -$45.1K | ﹤0.01% | 6827 |
|
|
2024
Q2 | $55K | Sell |
56,700
-13,800
| -20% | -$15.1K | ﹤0.01% | 5976 |
|
|
2024
Q1 | $111K | Buy |
+70,500
| New | +$85.1K | ﹤0.01% | 5471 |
|
|
2023
Q1 | – | Sell |
-1,400
| Closed | -$2K | – | 8885 |
|
|
2022
Q4 | $2K | Buy |
+1,400
| New | +$2.27K | ﹤0.01% | 8509 |
|
|
2022
Q3 | – | Sell |
-5,900
| Closed | -$10K | – | 9786 |
|
|
2022
Q2 | $10K | Buy |
5,900
+1,700
| +40% | +$2.92K | ﹤0.01% | 8259 |
|
|
2022
Q1 | $8K | Sell |
4,200
-100
| -2% | -$270 | ﹤0.01% | 9018 |
|
|
2021
Q4 | $16K | Sell |
4,300
-19,500
| -82% | -$88.8K | ﹤0.01% | 8587 |
|
|
2021
Q3 | $103K | Hold |
23,800
| – | – | ﹤0.01% | 6580 |
|
|
2021
Q2 | $101K | Buy |
23,800
+23,724
| +31,216% | +$115K | ﹤0.01% | 6711 |
|
|
2021
Q1 | $40K | Sell |
76
-77
| -50% | -$441 | ﹤0.01% | 6846 |
|
|
2020
Q4 | $82K | Buy |
153
+146
| +2,086% | +$793 | ﹤0.01% | 5641 |
|
|
2020
Q3 | $5K | Sell |
7
-240
| -97% | -$2.1K | ﹤0.01% | 7087 |
|
|
2020
Q2 | $247K | Buy |
247
+242
| +4,840% | +$1.52K | ﹤0.01% | 3759 |
|
|
2020
Q1 | $1K | Buy |
+5
| New | +$17 | ﹤0.01% | 7304 |
|
|
2019
Q2 | – | Sell |
-16
| Closed | -$6K | – | 7001 |
|
|
2019
Q1 | $6K | Buy |
16
+6
| +60% | +$28 | ﹤0.01% | 6388 |
|
|
2018
Q4 | $5K | Buy |
+10
| New | +$74 | ﹤0.01% | 6183 |
|
|
2018
Q3 | – | Sell |
-12
| Closed | -$14K | – | 7313 |
|
|
2018
Q2 | $14K | Buy |
12
+6
| +100% | +$75 | ﹤0.01% | 6116 |
|
|
2018
Q1 | $1K | Buy |
+6
| New | +$53 | ﹤0.01% | 5511 |
|
|
2017
Q4 | – | Sell |
-10
| Closed | -$3K | – | 5886 |
|
|
2017
Q3 | $3K | Buy |
+10
| New | +$62 | ﹤0.01% | 4708 |
|
|
2017
Q2 | – | Sell |
-10
| Closed | -$3K | – | 5980 |
|
|
2017
Q1 | $3K | Buy |
+10
| New | +$44 | ﹤0.01% | 4911 |
|
Other funds holding ADAP
Simplex Trading's ADAP Position: Q1 2026 in Review
Simplex Trading sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 18,610 shares — an estimated $483 sold.
Simplex Trading first reported a position in ADAP in Q2 2017 and held it in 25 quarters. The position peaked at $181K in Q1 2021. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.
- Simplex Trading reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
- Simplex Trading sold 18,610 Adaptimmune Therapeutics shares in Q1 2026, an estimated $483.
- Simplex Trading first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 25 quarters.
- Simplex Trading's Adaptimmune Therapeutics position peaked at $181K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.